MetLife Investment Management LLC Buys 1,500 Shares of Stryker Co. (NYSE:SYK)

MetLife Investment Management LLC boosted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 95,883 shares of the medical technology company's stock after buying an additional 1,500 shares during the period. MetLife Investment Management LLC's holdings in Stryker were worth $34,523,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $25,000. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the fourth quarter worth about $33,000. Finally, Activest Wealth Management purchased a new position in Stryker in the fourth quarter valued at about $36,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SYK shares. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a report on Thursday, January 30th. Wells Fargo & Company raised their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Royal Bank of Canada upped their target price on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price objective on Stryker in a report on Tuesday, March 4th. Finally, BTIG Research set a $403.00 target price on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $423.53.

Stryker Stock Performance

Shares of NYSE:SYK traded up $9.21 on Wednesday, hitting $357.33. The company's stock had a trading volume of 1,521,368 shares, compared to its average volume of 1,357,140. The company has a market capitalization of $136.39 billion, a price-to-earnings ratio of 46.05, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock's 50-day moving average is $369.25 and its two-hundred day moving average is $373.06.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 earnings per share. On average, equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.94%. Stryker's dividend payout ratio (DPR) is 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.